Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Blog Front Page BLOG POSTS Patents and Trade: Opportunities and Challenges in the Global Healthcare Market The Elixir of Faith and Deceit Executive Education Program on Health, Pharmaceuticals and Intellectual Property Data Exclusivity and Trips Flexibilities: Going Back to the Basics The Role of the Medicines Patent Pool (MPP) in the Context of the Global Access to Medicines Movement CATEGORIES COVID-19 10 Data Exclusivities 4 Deceptive Claims 1 Exhaustion 2 Experimental Use 1 IPAB 1 Patent Pools 2 Patents 13 Right to Health 1 TAMU 1 Trade Policy 1 TRIPS 12 TRIPS Flexibilities 2 Voluntary Licenses 1
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
